Ryan Kubota
Director of Investor Relations
Replay available
InnovAge Holding Corp. (NASDAQ: INNV) Q3 2025 earnings conference call, held 2025-05-06. Replay captured from the company's public earnings webcast.

Director of Investor Relations
CEO
CFO
President and COO
JP Morgan Analyst
William Blair & Company Analyst
KeyBank Analyst
Goldman Sachs Analyst
Good day, and thank you for standing by. Welcome to the InnoVAGE Third Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Ryan Kubota, Director of Investor Relations. Please go ahead. Thank you, Operator. Good afternoon, and thank you all for joining the InnovAge 2025 Fiscal Third Quarter Earnings Call. With me today is Patrick Blair, CEO, and Ben Adams, CFO. Michael Scarborough, President and COO, will also be joining the Q&A portion of the call. Today, after the market closed, we issued an earnings press release containing detailed information on our fiscal third quarter results. You may access the release on the Investor Relations section of our company website, innovates.com. For those listening to the rebroadcast of this call, we remind you that the remarks made herein are as of today, Tuesday, May 6, 2025, and have not been updated subsequent to this call. During our call, we will refer to certain non-GAAP measures. Reconciliation of these measures to the most directly comparable GAAP measures can be found in our earnings press release posted on our website. We may also make statements that are considered forward-looking, including those related to our 2025 fiscal year projections and guidance, future growth prospects and growth strategy, our clinical and operational value initiatives, Medicare ra...